,Canonical_Smiles,drug_name,drug_type,Label
0,CC(=O)c1cc2cccc(OC[C@H](O)CNC(C)C)c2o1,Befunolol,2D6-Substrate,negative
1,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,Levofloxacin,-,negative
2,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nn[nH]n3)c2)nc1OCCO,Tezosentan,-,negative
3,CNC(=O)Oc1cc(C)c(SC)c(C)c1,Methiocarb,2D6-Substrate,negative
4,C=CCSSCC=C,diallylsulfide,2E1-Substrate,negative
5,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Clopidogrel,-,negative
6,C=C(C)[C@@H]1CC=C(C)CC1,limonene_S,2C19-Substrate,negative
7,C=CCC1(C(C)C)C(=O)NC(=O)NC1=O,Aprobarbital,2B6-Inducer,negative
8,CCCCC[C@H](O)C=C[C@@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,Alprostadil,Multidrug_resistance_associated_protein_4-Substrate,negative
9,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,17_beta_estradiol,2C9-Substrate,negative
10,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2,Moracizine,-,negative
11,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12,Aldosterone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer,negative
12,CC(=O)Nc1nnc(S(N)(=O)=O)s1,Acetazolamide,-,negative
13,CNCCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,desmethyl_citalopram,2D6-Substrate,negative
14,CC1=CC(=O)c2ccccc2C1=O,Menadione,2E1-Substrate,negative
15,CCCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](O)CC(=O)O[C@H](C)CC=CC=C[C@H](O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(=O)CC,Rokitamycin,-,negative
16,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,Zaleplon,P450_HFLA-Substrate,negative
17,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminoglutethimide,-,negative
18,CNCCCN1c2ccccc2CCc2ccc(Cl)cc21,N_desmethyl_clomipramine,2D6-Substrate,negative
19,CN(C)CCC=C1c2ccccc2Sc2ccc(Cl)cc21,Chlorprothixene,3A4-Substrate,negative
20,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,Almotriptan,2D6-Substrate,negative
21,CC(=O)c1cc2ccccc2s1,2_acetylbenzothiophene,2E1-Substrate,negative
22,Cn1c(N)nc2c3cccnc3ccc21,2_amino_3_methylimidazo_4_5_f_quinoline,1A2-Substrate,negative
23,O=C(O)C=Cc1ccccc1,Bemiparin,SUL-Substrate,negative
24,NCCc1c[nH]c2ccc(O)cc12,5_hydroxy_tryptamine,2C19-Substrate,negative
25,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,Piroxicam,-,negative
26,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21,Cefmetazole,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
27,C=CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_13,3A4-Substrate,negative
28,CCC1(c2ccncc2)CCC(=O)NC1=O,Rogletimide,-,negative
29,COc1ccc2c(CN)cc(=O)oc2c1,MAMC,2D6-Substrate,negative
30,CCN(C)C=O,N_methyl_ethyl_formamide,2E1-Substrate,negative
31,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,Palonosetron,2D6-Substrate,negative
32,Nc1nc2ccc(OC(F)(F)F)cc2s1,Riluzole,-,negative
33,O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1,Thalidomide,CP2CI-Substrate,negative
34,CCCCCCOc1ccc2ccc(=O)oc2c1,7_hexoxy_coumarin,3A4-Substrate,negative
35,O=C1OC(c2ccc(O)c(S(=O)(=O)O)c2)(c2ccc(O)c(S(=O)(=O)O)c2)c2c(Br)c(Br)c(Br)c(Br)c21,Sulfobromophthalein,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
36,CC1O[C@@]2(CS1)CN1CCC2CC1,Cevimeline,2D6-Substrate,negative
37,CC12CCC3C(CCC4=CC(=O)C=CC43C)C1CCC(=O)O2,Testolactone,-,negative
38,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21,Pefloxacin,-,negative
39,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,Vecuronium,Methyltransferase-Inhibitor,negative
40,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Erythromycin,P450_HFLA-Substrate,negative
41,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,Topotecan,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
42,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,Tolcapone,Methyltransferase-Inhibitor,negative
43,CCN(C)N=O,NN_methyl_ethyl_nitrosoamine,2E1-Substrate,negative
44,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,Fulvestrant,3A4-Substrate,negative
45,CO[C@@]12CC[C@]3(C[C@H]1[C@](C)(O)C(C)(C)C)[C@@H]1Cc4ccc(O)c5c4[C@]3(CCN1CC1CC1)[C@@H]2O5,Buprenorphine,CP2CI-Substrate,negative
46,CC(C)(CO)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,w_OH_finasteride,3A4-Substrate,negative
47,CCC1(C2=CCCCC2)C(=O)NC(=O)NC1=O,Cyclobarbital,HLp2-Inducer,negative
48,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,Fentanyl,P450_HFLA-Substrate,negative
49,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,Ketoconazole,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,positive
50,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,Zafirlukast,2E1-Inhibitor,negative
51,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,Cytarabine,Multidrug_resistance_protein_1-Inducer,negative
52,CC(C)OC(=O)CCCC=CC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Latanoprost,Solute_carrier_organic_anion_transporter_family_member_2A1-Inhibitor,negative
53,CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@@H]2OC(=CCCCC(=O)O)C[C@@H]21,Epoprostenol,2C9-Substrate,negative
54,CCN(CC)CC(=O)Nc1c(C)cccc1C,Lidocain,CP2CI-Substrate,negative
55,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,Midazolam,P450_HFLA-Inhibitor,negative
56,Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl,Lindane,N_acetyltransferase-Inducer,negative
57,O=NN1CCC[C@H]1c1cccnc1,N_nitroso_nornicotine,3A4-Substrate,negative
58,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCN(CCO)CC1,Tiaramide,-,negative
59,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21,Yohimbin,2D6-Inhibitor,negative
60,C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Quinine,-,negative
61,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,Dextropropoxyphene,P450_HFLA-Inducer,negative
62,COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1,kaempferide,2C9-Substrate,negative
63,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1c1ccccc1[N+](=O)[O-],Aranidipine,-,negative
64,O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-],Sodium Edetate,3A4-Substrate,negative
65,CN(C)C=O,DMF,2E1-Substrate,negative
66,N#N,Nitrogen,Solute_carrier_family_15_member_1-Substrate,negative
67,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,Desloratadine,2D6-Inhibitor,negative
68,COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c[nH]c2c1,BPR_0L075,2E1-Substrate,negative
69,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,Amprenavir,2D6-Substrate,negative
70,CCC(c1ccc(O)c(F)c1)C(C)c1ccc(O)c(F)c1,Bifluranol,-,negative
71,CCCCCN(CCCCC)N=O,NN_diamyl_nitrosoamine,2E1-Substrate,negative
72,Cc1ccc(C(C)C)cc2c(C)ccc1-2,Guajazulen,1A2-Substrate,negative
73,NC(=O)c1cccnc1,Nicotinamide,2E1-Inhibitor,negative
74,N=C(N)NC(=N)NCCc1ccccc1,Phenformin,2D6-Substrate,negative
75,CN/C(=C\[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,ranitidine,2D6-Substrate,negative
76,O=C(OC[C@H](O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,Glafenine,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,positive
77,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,Papaverine,2D6-Substrate,negative
78,NC[C@H](O)c1ccc(O)cc1,Octopamine,2D6-Substrate,negative
79,CCc1cccc2c3c([nH]c12)[C@](CC)(CC(=O)O)OCC3,Etodolac,Canalicular_multispecific_organic_anion_transporter_1-Inhibitor,negative
80,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,Lamotrigine,GST-Inducer,negative
81,CCN(CC)N=O,NN_diethyl_nitrosoamine,2E1-Substrate,negative
82,CC(=O)Nc1ccc(O)cc1,Paracetamol,2E1-Inducer,negative
83,ClC=C(Cl)Cl,Trichloroethylene,2E1-Substrate,negative
84,Nc1nc([O-])c2c(n1)NCC(CNc1ccc(C(=O)NC(CCC(=O)[O-])C(=O)O)cc1)N2C=O.[Ca+2],Calcium folinate,-,negative
85,CCCCCCCCC=CCCCCCCCC(=O)O,Monoethanolamine Oleate,2E1-Substrate,negative
86,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1,Benoxaprofen,1A2-Inducer,negative
87,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,montelukast,2D6-Substrate,negative
88,O=C(OC1CC2CCC(C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-],Trospium chloride,-,negative
89,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,testosterone,2C19-Substrate,negative
90,CCCc1cc(=O)[nH]c(=S)[nH]1,Propylthiouracil,GST-Inhibitor,negative
91,O=c1ccc2nc3ccc(OCc4ccccc4)cc3oc-2c1,benzyl_oxy_resorufin,2D6-Substrate,negative
92,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,Bromocriptine,-,negative
93,CC[C@H](C)[C@H]1NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@@H](CCC(N)=O)NC1=O,Oxytocin,Solute_carrier_family_12_member_2-Inducer,negative
94,CN[C@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,Frovatriptan,-,negative
95,CN(C)C(=O)Oc1ccc[n+](C)c1,Pyridostigmine,3A4-Inducer,negative
96,O=C1[C@@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,Ezetimibe,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
97,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin_Mb12,3A4-Substrate,negative
98,Nc1ccc(C(=O)O)cc1,Aminobenzoic Acid,SUL-Substrate,negative
99,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Methylergometrine,-,negative
100,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21,Flurazepam,2E1-Inhibitor,negative
101,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,Brinzolamide,-,negative
102,CN1CCCN=C1C=Cc1cccs1,Pyrantel,2D6-Substrate,negative
103,COc1ccccc1OC[C@H]1CNC(=O)O1,Mephenoxalone,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
104,C[C@H]1O[C@@H]1P(=O)(O)O,Fosfomycin,GST-Substrate,negative
105,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,Mifepristone,P450_HFLA-Inhibitor,negative
106,C=CCC1([C@H](C)CCC)C(=O)NC(=O)NC1=O,Secobarbital,-,negative
107,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Cortisone,SUL-Inhibitor,negative
108,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,Benazepril,Aldosterone_synthase_ALDOS_Aldosterone_synthesizing_enzyme_Steroid_18_hydroxylase-Inhibitor,negative
109,CN(C)CCOC(c1ccccc1)c1ccccc1,Diphenhydramin,2D6-Substrate,negative
110,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
111,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,Azathioprine,Methyltransferase-Substrate,negative
112,COc1ccc(CCN(C)CCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,verapamil_R,2C8-Substrate,negative
113,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,Ibutilide,-,negative
114,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,Glimepiride,-,negative
115,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,MK_0457_tozasertib,2D6-Substrate,negative
116,NC(Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].[Na+],Levothyroxine sodium,-,negative
117,CC(O)(CC(=O)O)CC(=O)O,Meglutol,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
118,N[C@@H]1[C@@H](O)O[C@@H](CO)[C@H](O)[C@H]1O,Glucosamine,2E1-Substrate,negative
119,Clc1ccc(Cl)c(-c2cc(Cl)c(Cl)cc2Cl)c1,PCB_101,3A4-Substrate,negative
120,COP(=S)(OC)SCn1nnc2ccccc2c1=O,azinphosmethyl,2C19-Substrate,negative
121,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,Decitabine,Methyltransferase-Inhibitor,negative
122,C=C(C)C1CO1,isoprene_epoxide_2,2E1-Substrate,negative
123,O=c1[nH]c(=O)n([C@H]2CCCO2)cc1F,Tegafur,2E1-Substrate,negative
124,Fc1cccc2c1OC1CNCC1O2,Fluparoxan,-,negative
125,NC1=NC[C@@H]2c3ccccc3Cc3ccccc3N12,Epinastine,2D6-Inhibitor,negative
126,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,fluvoxamine,2D6-Substrate,negative
127,CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1,Delavirdine,2D6-Inhibitor,negative
128,O=c1[nH]c2cc(Cl)ccc2o1,chlorzoxazone,2E1-Substrate,negative
129,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,Zolpidem,P450_HFLA-Substrate,negative
130,NCC(=O)O,Glycine,GST-Inducer,negative
131,O=S1OCC2C(CO1)C1(Cl)C(Cl)=C(Cl)C2(Cl)C1(Cl)Cl,endosulfan,2C19-Substrate,negative
132,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,Codeine,P450_HFLA-Substrate,negative
133,CC(C)[C@H](N)C(=O)OC[C@H](CO)OCn1cnc2c(=O)nc(N)[nH]c21,Valganciclovir,Solute_carrier_family_15_member_2-Inhibitor,negative
134,CC(NCCCOc1cccc2ccccc12)C(F)(F)F,deshydroxy_trifluoro_propranolol,2D6-Substrate,negative
135,CCc1ccc(CCOc2ccc(C[C@@H]3SC(=O)NC3=O)cc2)nc1,Pioglitazone,2D6-Inhibitor,negative
136,CN(CC(=O)O)C(=N)NP(=O)(O)O,Fosfocreatine,Methyltransferase-Inhibitor,negative
137,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,Rupatadine,-,negative
138,C[C@@H]1NC(=O)[C@H](NC(=O)c2ncccc2O)[C@H](C)OC(=O)[C@@H](c2ccccc2)NC(=O)[C@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@H]2CCCN2C1=O,Virginiamycin,Methyltransferase-Inhibitor,negative
139,CCN(CC)C(=S)SSC(=S)N(CC)CC,Disulfiram,2E1-Substrate,negative
140,CCOC(=O)c1cncn1[C@@H](C)c1ccccc1,Etomidate,19A-Inhibitor,negative
141,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,Nefazodone,P450_HFLA-Inhibitor,negative
142,CCN(CC)C(=S)SC,DDTC_Me,2E1-Substrate,negative
143,CN(C)S(=O)(=O)CCNC(=O)N(CCCl)N=O,tauromustine,2D6-Substrate,negative
144,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O,Griseofulvin,-,negative
145,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cinnarizine,2D6-Substrate,negative
146,Cc1ccc(=O)n(-c2ccccc2)c1,Pirfenidone,1A2-Substrate,negative
147,CCO[C@H]1O[C@@H]2OC3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,beta_arteether,3A4-Substrate,negative
148,FCOC(C(F)(F)F)C(F)(F)F,Sevoflurane,2E1-Substrate,negative
149,CN1CCN2c3ccccc3Cc3ccccc3[C@@H]2C1,mianserin_R,2D6-Substrate,negative
150,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,Ranitidine,2D6-Substrate,negative
151,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,Tryptophan,1B1-Inducer,negative
152,CCCO,Propanol,-,negative
153,CCCNCc1cc(=O)oc2cc(OC)ccc12,PMAMC,2D6-Substrate,negative
154,Oc1c(I)cc(Cl)c2cccnc12,Clioquinol,SUL-Inhibitor,negative
155,Nc1nc2[nH]cnc2c(=S)[nH]1,Tioguanine,Solute_carrier_family_28_member_3-Substrate,negative
156,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Beclometasone,-,negative
157,O=c1c2ccccc2nc2n1CCc1c-2[nH]c2ccccc12,rutaecarpine,2E1-Substrate,negative
158,Cc1cccc(C)c1NC(=O)[C@H](C)N,Tocainide,-,negative
159,CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2,2_acetylamino_fluorene,1A2-Substrate,negative
160,Clc1ccc(CS[C@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,Sulconazole,2E1-Inhibitor,negative
161,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,Quercetin,-,negative
162,C#CC1(O)C=CC2C3CCC4=CC(=O)CCC4C3CCC21CC,Gestodene,-,negative
163,O=C(O)c1ccccc1O,Salicylic Acid,2E1-Inducer,negative
164,Cc1c2ccccc2nc2c1ccc1ccccc12,7_methyl_benzacridine,1A2-Substrate,negative
165,CCCCCCCCC,nonane,2E1-Substrate,negative
166,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Medroxyprogesterone,-,negative
167,CC(C)(C)C(O)C=Cc1ccc2c(c1)OCO2,Stiripentol,-,negative
168,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C,Tinidazole,19A-Inhibitor,negative
169,CON=C(C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1,Cefepime,Solute_carrier_family_22_member_5-Inhibitor,negative
170,COCC[C@H]1CC2CN3CCc4c([nH]c5ccccc45)[C@](C(=O)OC)(C2)C13,18_methoxy_coronaridine,2D6-Substrate,negative
171,CN[C@@H](C)[C@H](O)c1ccccc1,Ephedrin,SUL-Substrate,negative
172,CC(C)O,Isopropanol,2E1-Inducer,negative
173,O=C1CN(N=Cc2ccc([N+](=O)[O-])o2)C(=O)N1,Nitrofurantoin,ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
174,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@@H]1c1cccc([N+](=O)[O-])c1,Nimodipine,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,positive
175,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Atazanavir,P450_HFLA-Inhibitor,negative
176,C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2,Memantine,2D6-Inhibitor,negative
177,CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc21)OCOC(=O)C(C)(C)C,Adefovir Dipivoxil,2C9-Inhibitor,negative
178,CC(C)(C(=O)O)c1ccc([C@@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,Fexofenadine,2D6-Inhibitor,negative
179,c1ccc2ncccc2c1,quinoline,2E1-Substrate,negative
180,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,Paclitaxel,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
181,CC(C)COC[C@H](CN(Cc1ccccc1)c1ccccc1)N1CCCC1,Bepridil,2D6-Substrate,negative
182,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,Captopril,Methyltransferase-Substrate,negative
183,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,Arbekacin,N_acetyltransferase-Substrate,negative
184,CN1C2CCC1CC(OC(c1ccccc1)c1ccccc1)C2,Benzatropine,2D6-Substrate,negative
185,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,Pimozide,2E1-Inhibitor,negative
186,CN(C)C(=N)NC(=N)N,Metformin,Multidrug_and_toxin_extrusion_protein_1-Substrate,negative
187,CCCC(C)(COC(N)=O)COC(N)=O,Meprobamate,2E1-Substrate,negative
188,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21,Norfloxacin,P450_HFLA-Inhibitor,negative
189,CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1C2=Cc1ccc(Cl)cc1,Lumefantrine,-,negative
190,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,Simvastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
191,Cc1nc2c([nH]1)c(=O)n(C)c(=O)n2Cc1ccco1,Furafylline,-,negative
192,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,Androstanolone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Substrate,negative
193,CCCCCC,hexane,2E1-Substrate,negative
194,C[C@@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@H]2O,Estradiol,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
195,CC(C)n1c(C=C[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,Fluvastatin,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
196,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,all_trans_retinal,2D6-Substrate,negative
197,O=S(=O)([O-])[O-],Sodium Sulfate,P450_HP-Inducer,negative
198,NC(=O)CC[C@H](N)C(=O)O,Levoglutamide,Neutral_amino_acid_transporter_B0-Substrate,negative
199,CCN[C@@H]1C[C@@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,Dorzolamide,2E1-Substrate,negative
200,CCNc1nc(NC(C)(C)C)nc(SC)n1,terbutryn,2C19-Substrate,negative
201,CN(C)c1ccc(C2CC3(C)C(CCC3(O)CCCO)C3CCC4=CC(=O)CCC4=C23)cc1,Onapristone,-,negative
202,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,Oseltamivir,Solute_carrier_family_15_member_1-Substrate,negative
203,CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,Dexloxiglumide,-,negative
204,CC1=C(C)C(=O)C([C@H](CCCCCC(=O)O)c2ccccc2)=C(C)C1=O,Seratrodast,-,negative
205,Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2,Pilsicainide,-,negative
206,CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],Pyridostigmine bromide,-,negative
207,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,Loperamide,2D6-Substrate,negative
208,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,Irinotecan,P450_HFLA-Substrate,negative
209,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,thalidomide,2C19-Substrate,negative
210,O=C(O)C/C=C/C[C@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,bisnor,3A4-Substrate,negative
211,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,Chlorpropamide,2C19-Substrate,negative
212,CC(N)Cc1ccc2c(c1)OCO2,MDA_tenamfetamine,2D6-Substrate,negative
213,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,Oxycodone,19A-Inhibitor,negative
214,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,Cinacalcet,2D6-Substrate,negative
215,N=O,Nitric Oxide,GST-Inducer,negative
216,O=C(CO)NCCCOc1cccc(CN2CCCCC2)c1,Roxatidine,2D6-Substrate,negative
217,CN1CCN2c3ccccc3Cc3ccccc3[C@H]2C1,Mianserin,2D6-Substrate,negative
218,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,Nimesulide,2C9-Inhibitor,negative
219,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,Clofibrate,4A11-Substrate,negative
220,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Hydrocodone,2D6-Substrate,negative
221,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,Itraconazole,ATP_binding_cassette_sub_family_G_member_2-Inhibitor,positive
222,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,Ranolazine,-,negative
223,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,Idebenone,1A2-Substrate,negative
224,CC(C)=O,Acetone,-,negative
225,CC(=O)N[C@H](CS)C(=O)O,Acetylcysteine,Multidrug_resistance_protein_1-Inducer,negative
226,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2,Camphora,GST-Inducer,negative
227,Cc1cnc2ccc3c(nc(N)n3C)c2n1,2_amino_3_8_dimethylimidazo_4_5_f_quinoxaline,1A2-Substrate,negative
228,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,Escitalopram,2D6-Substrate,negative
